Infrarenal AAA and Iliac Aneurysm Decision-Making and Medical Management

19.1What this chapter decides

A detected infrarenal abdominal aortic aneurysm creates a surveillance problem long before it becomes an operation. The clinician must decide when the patient is safer continuing observation and when the balance shifts toward elective repair. This depends on aneurysm size, sex, interval growth, morphology, ultrasound reliability, operative fitness, endovascular anatomy, and the patient’s view of risk. Society thresholds define the point at which repair should be actively planned, but the clinician must still determine whether the individual patient will benefit from intervention.

Management begins with a stable, asymptomatic AAA below the repair threshold. In that setting, the main clinical decisions are the imaging interval, the reliability of the modality, and whether anything about the aneurysm’s behavior has changed enough to shorten the interval. Once the aneurysm approaches threshold, the conversation changes. The focus shifts to whether the patient is fit enough, whether the anatomy permits a durable repair, and whether the anticipated benefit of preventing rupture exceeds the perioperative and long-term risks. The threshold must be integrated with growth pattern, saccular morphology, and patient-specific competing risk.

Medical management sits alongside surveillance because many patients live with a small or moderate AAA for years. The clearest pharmacologic promise is cardiovascular risk reduction, especially with statin therapy, while AAA-specific claims about growth modification remain more uncertain. The same caution applies in reverse for potentially harmful exposures: fluoroquinolone antibiotics have an aortic-event signal in observational and pharmacovigilance data, so the presence of known AAA should influence antibiotic choice when an effective alternative exists. Glucose-lowering therapies, particularly metformin, show an inverse observational association with AAA presence and growth, but that association should not be translated into an AAA-specific prescription in a patient who does not otherwise need the drug.

Iliac aneurysms require their own branch in the pathway. A common iliac artery aneurysm may be discovered with an infrarenal AAA, may determine the distal seal strategy during EVAR, or may appear as an isolated aneurysm with its own repair threshold. Internal iliac aneurysms are different again: they are less common, more anatomy-dependent, and tightly linked to pelvic perfusion decisions. The shared theme is that the operation is planned around durable exclusion while preserving clinically important flow whenever feasible.

19.2Elective-repair threshold for asymptomatic fusiform AAA

The elective-repair threshold for an asymptomatic fusiform infrarenal AAA is best understood as the point at which rupture prevention usually begins to outweigh the risk of planned repair. In men, contemporary society guidance places that reference point near 55 mm: the SVS 2018 practice guideline gives a strong recommendation for repair at 5.5 cm SVS 2018, the ESVS 2024 guideline recommends elective repair at 55 mm Editor's Choice European 2024, and the KVSS 2026 guideline places the men’s reference point at 50–55 mm in an Asian-region population KVSS 2026. These values represent decision thresholds rather than emergency cut-offs. A stable 54 mm fusiform AAA in a fit man behaves similarly to a stable 55 mm aneurysm, but the threshold marks the point at which the vascular team should normally plan elective repair rather than continue routine surveillance.

Women require a separate discussion because the diameter-risk relationship and body-size context are not identical to those in men. SVS 2018 frames elective repair in women in the 5.0–5.4 cm band as a conditional recommendation SVS 2018, while ESVS 2024 explicitly recommends against repair below 50 mm in women Editor's Choice European 2024. These statements require integrating the relevant society recommendation, measurement method, anatomy, fitness, and patient preference. In a small woman with a near-threshold aneurysm and favorable anatomy, the conversation may begin earlier than it would in a larger man; in a frail woman with stable morphology and high competing mortality, surveillance may remain the better choice even near the threshold.

The threshold also changes character when morphology or growth is atypical. Fusiform, slowly enlarging infrarenal AAA is the population in which the 55 mm reference point is most useful. Saccular morphology, rapid expansion, symptoms, poor measurement reliability, or concern that a future endovascular option will be lost can bring the repair conversation forward. Conversely, very high operative risk, hostile anatomy that would make repair non-durable, or limited life expectancy can move the decision toward continued surveillance even after a numeric threshold is crossed. Recent analyses of real-world practice show variation and drift away from the original 5.5 cm reference point in some centers, which reinforces the need to distinguish legitimate individualisation from threshold erosion Decreasing prevalence centers 2024 · Vascular Surgeons Abdominal 2025.

Clinical assessment involves three steps: determining if the aneurysm has reached the society threshold for the patient’s sex and population; assessing if the anatomy is suitable for a durable repair; and evaluating whether the patient’s fitness and preference make elective repair a better option than continued surveillance. This sequence prevents two common errors: operating below threshold because repair is technically possible, and delaying threshold repair because the aneurysm remains asymptomatic.

19.3Surveillance intervals before the threshold is reached

Surveillance of a small AAA is an active management plan to identify the patient whose aneurysm remains safely below threshold, the patient whose measurement is unreliable, and the patient whose growth or morphology has changed the risk enough to trigger repair assessment. The SVS 2018 schedule ties ultrasound interval to the current diameter band: 36 months for an AAA measuring 3.0–3.9 cm, 12 months for 4.0–4.9 cm, and 6 months once the aneurysm reaches 5.0–5.4 cm SVS 2018. Larger aneurysms have less margin before reaching the repair threshold, requiring shorter intervals even when asymptomatic.

European guidance follows a comparable band-based strategy and adds an important growth trigger. ESVS 2024 treats serial growth of at least 10 mm per year as a reason to re-measure and reassess the patient rather than waiting for the next band-based scan Editor's Choice European 2024. A single larger measurement should be checked for technique, plane, and modality before it is allowed to drive an operation; confirmed rapid growth should then prompt cross-sectional imaging or multidisciplinary repair assessment, especially when the aneurysm is near threshold. The clinician should also be alert to the false reassurance created by an apparently small aneurysm that has poor ultrasound windows or inconsistent measurement technique.

Ultrasound remains the usual surveillance modality for straightforward infrarenal AAA below threshold, but the modality should change when the clinical question changes. If the question is “has this small aneurysm enlarged within its surveillance band?”, ultrasound is usually adequate. If the question is “can this patient undergo durable repair?”, cross-sectional imaging becomes necessary because neck length, angulation, thrombus, calcification, iliac access, and distal landing zones determine the operative plan. Inadequate ultrasound windows, discordant measurements, saccular morphology, or a strong clinical concern should therefore move the patient out of routine band surveillance and into targeted reassessment.

The surveillance visit should also reset the patient’s understanding of the plan. A 3.4 cm AAA is not “normal,” but it is usually a long surveillance problem. A 5.2 cm AAA in a man is not yet automatically repaired under the SVS band, but it is close enough that the next scan and the first repair conversation should be scheduled deliberately SVS 2018. A near-threshold aneurysm with growth approaching the ESVS trigger deserves re-measurement and repair assessment rather than reassurance Editor's Choice European 2024.

19.4Medical therapy: what we can promise the patient

Medical therapy for AAA should be presented with clear boundaries. Medication will not make the aneurysm disappear or reliably stop growth, but patients with AAA have vascular risk that must be treated. Statin therapy is consistently framed as cardiovascular risk reduction in AAA care, and the available observational synthesis and registry follow-up support improved long-term survival after elective AAA repair among patients receiving statins Meta-analysis suggests statins 2022 · Effect Statin Therapy 2018 · Statin therapy after 2024. Pooled analyses also suggest favorable AAA-related signals, but a growth-rate effect has not been established by a randomized AAA-targeted trial, so statins should not be sold to patients as a proven aneurysm-shrinking drug Effect statins 2022.

This distinction is clinically important because it prevents therapeutic overstatement while still ensuring that useful treatment is not withheld. A patient under AAA surveillance should understand that statin therapy is part of vascular risk management and may improve long-term outcomes after repair, but the surveillance schedule remains necessary. Continuing ultrasound follow-up after starting a statin is not a failure of the medication; it reflects the fact that the aneurysm-specific endpoint remains uncertain. The same logic applies after repair: long-term survival benefit in observational data supports statin continuation, but it does not replace graft surveillance, endoleak assessment after EVAR, or management of other vascular beds.

Fluoroquinolone antibiotics should be discussed differently. The issue is not a treatment benefit but a potential exposure risk. Fluoroquinolone use has been associated with aortic aneurysm and dissection events in observational and pharmacovigilance data; clinicians should choose an effective non-fluoroquinolone alternative when one exists for a patient with known AAA or aortic disease Fluoroquinolones 2026. This should be framed as risk avoidance rather than alarm. Absolute event rates may be low, and sometimes the antibiotic is clinically necessary, but known AAA should be part of the prescribing decision.

Metformin and other glucose-lowering therapy sit in a third category: biologically and epidemiologically interesting, but not yet an AAA-specific prescription. Pooled observational analyses report an inverse association between metformin or glucose-lowering therapy and AAA presence or growth Association metformin use 2024 · Bell 2026 · Relationship between metformin 2020. Laboratory work using AAA patient-derived smooth muscle cells adds mechanistic interest, but it does not convert the observational signal into a clinical indication for a patient without an independent metabolic reason to use the drug Metformin Improves Function 2025. The correct promise is therefore narrow: treat diabetes well on its own merits, recognise the AAA signal as hypothesis-generating, and do not start glucose-lowering therapy solely to manage an aneurysm.

The patient-facing summary can be simple. Statins are generally part of vascular risk care and have supportive survival data in AAA populations. Fluoroquinolones should usually be avoided when a good alternative is available in a patient with known aortic disease. Metformin should be continued or prescribed for appropriate diabetes indications, but not as stand-alone AAA therapy. None of these choices removes the need for diameter-based surveillance or timely repair assessment.

19.5Iliac aneurysm: when the decision branches off the AAA pathway

Iliac aneurysm management begins by separating three questions that are often conflated. Is the iliac aneurysm isolated, or is it part of an infrarenal AAA repair plan? Is the diseased segment the common iliac artery, where the issue is usually distal seal and expansion risk, or the internal iliac artery, where pelvic perfusion and rupture risk dominate? And can at least one internal iliac artery be preserved without compromising durable exclusion? Answering these questions prevents the iliac decision from being treated as a minor extension of the aortic decision.

For isolated common iliac artery aneurysms, current European guidance usually brings repair planning into view around 35–40 mm, with the exact decision modified by morphology, growth, neck anatomy, and the feasibility of preserving internal iliac flow Editor's Choice European 2024 · Common iliac artery 2008. Smaller asymptomatic common iliac dilatations are generally followed rather than repaired immediately. The operative threshold becomes more complex when a common iliac aneurysm is discovered during AAA planning: the iliac lesion may determine whether a standard iliac limb can seal, whether an iliac branch device is needed, or whether open reconstruction is a better way to achieve durable exclusion.

Internal iliac aneurysms are less common in isolation and should not be managed by borrowing the common iliac threshold. Series-level evidence and case reports document rupture in isolated internal iliac aneurysm and after previous endovascular treatment, including situations where no endoleak is visualised Ruptured Isolated Internal 2023 · Internal Iliac Artery 2022. Symptomatic, rapidly growing, or anatomically threatening internal iliac aneurysms therefore warrant repair planning on their own terms, even when the infrarenal aorta does not meet an AAA threshold Outcomes open endovascular 2014 · Endovascular treatment isolated 2011. The decision is often less about a single diameter and more about whether the aneurysm can rupture into the pelvis, compress adjacent structures, or complicate a planned aorto-iliac repair.

The operative strategy should also protect pelvic perfusion whenever feasible. Routine hypogastric exclusion may be technically simple, but bilateral loss of internal iliac flow can cause disabling buttock claudication and, in selected patients, more serious pelvic ischemia. Endovascular hypogastric aneurysm repair and iliac branch-device strategies have therefore become important options when the anatomy allows preservation of at least one internal iliac artery Endovascular treatment hypogastric 2019 · Using bilateral iliac 2011. The preservation decision is especially important in bilateral iliac aneurysm disease, prior pelvic intervention, marginal collateral circulation, or when a future aortic repair may consume remaining landing zones.

The iliac plan must be explicit before committing to the aortic plan. A patient with an infrarenal AAA and ectatic iliac arteries may be a straightforward EVAR candidate today but lose distal seal durability later if the iliac disease is ignored. A patient with a common iliac aneurysm near 40 mm may need repair even when the aorta is smaller than the AAA threshold. A patient with an internal iliac aneurysm may need a pelvic-flow strategy rather than simple embolisation. In all three settings, the iliac anatomy is not an afterthought; it is part of the repair indication and durability assessment.

19.6Shared decision-making at the threshold

Shared decision-making in asymptomatic AAA is the method for applying guidelines to a patient whose risk is shaped by more than diameter. The threshold identifies when repair should be seriously considered; the shared decision determines whether repair now, further surveillance, or additional assessment best matches the patient’s anatomy, fitness, and priorities. Literature on intact AAA management emphasises that fitness, sex, anatomy, and patient preference all reshape the timing of elective repair in real practice Shared Decision Making 2023 · Shared decision making 2019.

The conversation is most straightforward when all signals point in the same direction. A fit man with an asymptomatic fusiform 56 mm infrarenal AAA, favorable anatomy, and low competing risk usually enters elective repair planning under the major society thresholds Editor's Choice European 2024 · SVS 2018. A patient with a 38 mm aneurysm and stable measurements usually remains in surveillance. The difficult cases are the ones around the threshold: a frail patient with a 55 mm aneurysm, a woman in the 50–54 mm band, a patient with rapid growth but uncertain measurement reliability, or a patient whose anatomy makes EVAR easy now but possibly impossible later. These are the patients in whom the threshold must be combined with operative risk, durability, and the patient’s tolerance of uncertainty.

Quality-of-life data from early endovascular repair of small AAA did not show a clear advantage over careful surveillance, which supports the principle that technically feasible early EVAR should not automatically displace threshold-based observation Quality life patients 2011. Below threshold, in a stable asymptomatic patient, the expected benefit of early repair may be too small to justify the procedural and long-term device-related risks. Surveillance is therefore an active safety strategy, not therapeutic neglect.

A useful shared-decision conversation gives the patient four pieces of information. First, where the aneurysm sits relative to the relevant society threshold. Second, whether the measurement is reliable and whether growth has been confirmed. Third, what repair would involve for this anatomy, including the likely durability and need for follow-up. Fourth, what continued surveillance means: the next imaging date, the trigger for earlier assessment, and the symptoms that should prompt urgent evaluation. This structure keeps the discussion concrete and prevents both false reassurance and fear-driven early intervention.

The decision may reasonably open earlier than the diameter alone suggests when there is saccular morphology, confirmed rapid growth, strong family-history concern, borderline anatomy that may lose an endovascular option, or iliac disease that is already nearing its own repair threshold. It may also reasonably open later when the patient has severe competing illness, stable slow growth, anatomy that would make repair high-risk or non-durable, or a clear preference for surveillance after understanding the risks. The final recommendation should be documented as a balance of rupture prevention, operative risk, anatomic durability, and patient goals, rather than as a diameter number copied into a clinic letter.